NasdaqGS:ALNYBiotechs
Is It Too Late to Consider Alnylam Pharmaceuticals After Its Huge 2025 Share Price Surge?
Wondering if Alnylam Pharmaceuticals at around $412 a share is still a smart buy after its huge run, or if the upside has already been priced in.
The stock is down 11.3% over the last week and 8.7% over the past month, but even after that pullback it is still up 76.6% year to date and 68.2% over the last 12 months.
Those moves have come as investors refocus on Alnylam's RNAi drug pipeline, major partnerships with big pharma, and the growing commercial traction of its approved therapies. The...